Stock Events

Oncolytics Biotech 

C$1.68
46
-C$0.07-4% Wednesday 19:59

Statistics

Day High
1.74
Day Low
1.62
52W High
2.46
52W Low
1.15
Volume
175,570
Avg. Volume
94,974
Mkt Cap
142.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

13
NOV
Earnings
 

Earnings

13NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.11
-0.09
-0.06
-0.04
Expected EPS
-0.07524194145
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONC.TO. It's not an investment recommendation.
Alphabet
78395
GOOGL
Apple
68177
AAPL
Microsoft
63621
MSFT
Amazon
59331
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap179.38B
Amgen is involved in developing oncology treatments, including oncolytic virus therapies, directly competing with Oncolytics Biotech's approach to cancer treatment.
Merck
MRK
Mkt Cap300.25B
Merck's extensive portfolio in oncology, including immunotherapy treatments, positions it as a competitor in the cancer treatment space, overlapping with Oncolytics Biotech's market.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb offers a range of cancer treatments, including immunotherapies that compete with Oncolytics Biotech's viral-based cancer therapies.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences, with its focus on oncology and viral treatments, competes in the same space as Oncolytics Biotech, especially in the development of innovative cancer therapies.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a broad oncology division, including the development of treatments that could compete with Oncolytics Biotech's oncolytic virus therapy approach.
Novavax
NVAX
Mkt Cap1.98B
Novavax, while primarily known for vaccines, is exploring cancer vaccine treatments that could potentially compete with Oncolytics Biotech's viral-based therapies.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical division Janssen, develops a variety of oncology treatments that could compete with Oncolytics Biotech's approach to cancer therapy.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals focuses on developing monoclonal antibodies for cancer treatment, a method that could be seen as complementary or competitive to Oncolytics Biotech's viral therapies.
Sorrento Therapeutics
SRNE
Mkt Cap3.31M
Sorrento Therapeutics is involved in the development of new therapies for cancer, including approaches that could compete with or complement Oncolytics Biotech's oncolytic virus strategy.
Vir Biotechnology
VIR
Mkt Cap1.13B
Vir Biotechnology, while focusing on infectious diseases, is exploring the potential of using viral vectors for therapeutic purposes, which could intersect with Oncolytics Biotech's cancer treatment strategies.

About

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Show more...
CEO
Mr. Wayne F. Pisano M.B.A.
Country
CA
ISIN
CA6823108759

Listings

TO
CA
ONC.TO
XNAS
US
ONCY